OBJECTIVES: To measure utility (risk preference) of individuals deciding to take a multiple sclerosis (MS) drug given varying risks/benefi ts. METHODS: A computerized measure based on ProSPEQT software was developed to measure Standard Gamble utility. 45 healthy individuals were presented with 9 health states varying MS disease severity (mild, moderate, severe) and asked their preferences to remain in that state or gamble on taking a drug with varying probabilities of 3 levels of MS improvements (mild, average, substantial) but also corresponding probabilities of death. Student's t-test analyzed affects of gender, age-groups, education, and MS experience on utility. RESULTS: Subjects ranged from 16-69 years (mean 40 years) and 44.4% knew someone with MS. In general, healthy individuals were willing to accept substantial risk of death for even mild MS improvements and accepted more risk for severe MS and greater disease improvements. The lowest mean score was for mild MS improvement given mild MS (0.082; 95% CI [0.045-0.120]). The highest score was for substantial MS improvement given severe MS (0.382; 95% CI [0.295-0.469]). Only education signifi cantly affected utility for mild improvement in mild MS (p 0.03). Individuals with bachelor's degree or less had 7.7% higher score than post-graduates. CONCLUSIONS: We found it surprising how much risk of death healthy individuals were willing to accept (8-38%). This is much greater than the 1/1000 actual risk for natalizumab in MS treatment, which the FDA removed from the market. MS patients' voiced preferences helped get that drug back on the market, showing importance of shared health decision-making. The FDA and physicians might fi nd it diffi cult to approve or prescribe drugs with 38% risk of death. However, these preferences indicate healthy individuals may be less risk-averse than the FDA or physicians, emphasizing the importance of including the public when weighing risks and benefi ts of drugs.
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RISK OF DIABETES ASSOCIATED WITH THE USE OF ATYPICAL ANTIPSYCHOTICS IN CHILDREN AND ADOLESCENTS -A TEXAS MEDICAID STUDY
Nagar SP g , Mehta S, Zweifel P, Chen H P P University of Houston, Houston, TX, USA OBJECTIVES: To examine the risk of developing diabetes among children and adolescents who received atypical antipsychotic drug. METHODS: This study is a retrospective cohort analysis using [2003] [2004] Texas Medicaid claims data. Patients were included in the cohort if they met the following criteria: 6 to 18 years of age, new users of atypical antipsychotics and had not received a diagnosis of diabetes (ICD-9-CM code: 250.xx) or a prescription claim of an anti-diabetic drug both before and one month after the initiation of an antipsychotic treatment. Risk of newly developed diabetes following antipsychotic treatment was observed during a 12 month follow-up period. Kaplan-Meier survival curves and Cox proportional-hazards regression model were employed to examine the time dependent risk (hazard) of diabetes and hazards ratio were obtained. Age, gender, race and exposure to other diabetogenic medications were controlled in the analysis. RESULTS: A total of 4096 patients were identifi ed as new atypical antipsychotic users. The average age of the cohort was 11 years, most of the patients were male (65%), and Hispanics (36.5%). Cox-proportional hazard model analysis revealed no signifi cant association between use of atypical antipsychotic use and risk of diabetes (Hazards Ratio, HR 1.11, 95% CI 0.81-1.53). Children in the older age group of 15-18 years, females and Hispanics had higher risk of developing diabetes. Concurrent treatments with corticosteroids, beta-blockers, thiazides and antidepressants were also associated with increased incidence of diabetes. CONCLUSIONS: Our results indicate that there is no increase in the risk of developing diabetes in pediatric patients receiving atypical antipsychotics. The discrepancy in the fi ndings between adults and children implies that psychotropic medications might function differently in pediatric population from adults. It is necessary to comprehensively assess the risks associated with common off-label medications, such as atypical antipsychotics, in children and adolescents.
RA3 A BAYESIAN DECISION-ANALYTIC ECONOMIC MODEL TO OPTIMIZE ALLOCATION OF RISK IN PAY-FOR-PERFORMANCE PAYMENT ARRANGEMENTS
Mallick R 1 , Hollenbeak C 2 1 Risk Sharing Solutions, Collegeville, PA, USA, 2 Penn State College of Medicine, Hershey, PA, USA OBJECTIVES: Performance-based payment arrangements for innovative drugs seek to allocate fi nancial risk of interventions between manufacturers and payers. Given operational challenges in monitoring real-world outcomes, effective risk sharing mechanisms may require prediction of incremental survival/quality-adjusted life years (QALYs) conditional on surrogate markers, for example, complete remission (CR) or partial remission (PR). In accepting a risk-sharing arrangement that reimburses only for remitters, payers should minimize the "false-positive" (FP) risk: early remitters who subsequently have limited QALYs. Manufacturers should minimize the "falsenegative" (FN) risk: early non-remitters who subsequently have prolonged QALYs.
A Bayesian decision framework can be used to choose among multiple likelihood (predictive) priors to optimize the posterior economic risk trade-off for payers and manufacturers. METHODS: A Bayesian decision-analytic, hypothetical data-based, cost-effectiveness model was developed. Prior probabilities and QALYs were assigned for 6-, 3-, and 1-month survival, as were treatment costs. A plausible prior likelihood (predictive) structure represented the (ROC) relationship between the sensitivity and specifi city of CR/PR in predicting survival. Expected (posterior) probabilities of survival, conditional on CR/PR, were generated. At a threshold of $50,000/QALY, the cost-effectiveness of the intervention, conditional on achieving CR/PR, and an optimal sensitivity-specifi city trade-off was derived. RESULTS: At a hypothetical treatment cost of $5,000/month for a 4-month cycle, a minimal FP of 13% (maximum specifi city of 87%) and a minimal FN of 33% (maximum sensitivity of 67%) emerged as necessary to be accepted by payers and manufacturers respectively to ensure viable risksharing. At higher sensitivity, payer risk did not meet the reimbursement threshold, while at higher specifi city, manufacturers would assume excessive fi nancial risk. Other illustrations will be discussed. CONCLUSIONS: Manufacturers should propose evidence-based payment arrangements that utilize clinical trial data to develop economic implications of being at various points on the ROC curve in order to optimize the trade-offs between payer and manufacturer incentives.
RA4 METABOLIC SYNDROME RISK FACTORS FOR NATIVE BORN AND FIRST GENERATION ADOLESCENTS (12-17) IN THE UNITED STATES
Hufstader MA 1 , Sias S 1 , Vaidya V 2 , White-Means S 1 1 University of Tennessee Health Science Center, Memphis, TN, USA, 2 University of Tennessee, Memphis, TN, USA OBJECTIVES: To contrast the factors that are associated with metabolic syndrome risk for both adolescents overall and Hispanic adolescents in the U.S. METHODS: At risk is defi ned as having three or more of the following: elevated fasting glucose, elevated SBP, elevated DBP, elevated triglycerides, elevated BMI, elevated waist circumference, or low HDL. Logistic regression and NHANES 2003-2006 data were used to examine the impact on metabolic syndrome risks; gender, race, ethnicity, immigrant status, income, insurance, parental education, activity levels, number of school lunches and breakfasts per week, milk consumption, language preference, and number of meals outside the home per week. Adolescents in the United States overall are compared with Hispanic adolescents in the U.S. A signifi cance level of 0.05 was used. Weighted sample sizes for Hispanic adolescents and adolescents in the U.S. are 8,178,714, and 50,837,204 . RESULTS: Major differences include the decreased risk (42%) for adolescent females overall in the U. S., and the increased risk (17%) for Hispanic females in the U.S. Notably, for those Hispanics that are fi rst generation, their risk is increased by 65%. For adolescents overall in the U.S., low or middle income levels increase risk three times, while low and middle income level Hispanic adolescents in the U.S. have a risk decrease of 77% and 69% respectively. For every meal eaten outside the home per week (excluding school meals) the risk increases for adolescents in the U.S. by 4% and by 13% for Hispanic adolescents in the U.S. CONCLUSIONS: These adolescents are at risk for acute cardiovascular endpoints, higher medical utilization and expenditure, and lower quality of life. Interventions should focus on education regarding healthy eating outside the home with limited resources. This analysis is the high price of acculturation for Hispanic fi rst generation adolescents.
PODIUM SESSION IV: RESPIRATORY-RELATED DISORDERS -Outcomes Research & Health Care Policy Studies
RR1 QUARTERLY ASSESSMENT OF SHORT ACTING b-AGONIST USE AS A PREDICTOR OF SUBSEQUENT HEALTH CARE SERVICES USE FOR ASTHMATICS IN THE U.S.
Blanchette CM 1 , Silver H 1 , Petersen H 1 , Kamble S 2 , Meddis D 3 , Gutierrez B 3 1 Lovelace Respiratory Research Institute, Albuquerque, NM, USA, 2 The University of North Carolina at Charlotte, Charlotte, NC, USA, 3 AstraZeneca, Wilmington, DE, USA OBJECTIVES: Previous research has shown that high utilization of short-actingagonists (SABA) is associated with asthma exacerbations, however annual assessments present signifi cant barriers to real-time assessment needed for effective intervention. We explored a quarterly assessment of high SABA utilization patterns on subsequent asthma exacerbations. METHODS: A retrospective cohort study conducted using PHARMetrics database included health plan members (aged 6-56 years; n 93,604) with asthma and two-year continuous enrollment between 7/2003-6/2007, 1 hospitalization/emergency department (ED) or 2 outpatient claims of International Classifi cation of Diseases, 9th Revision, Clinical Modifi cation (ICD-9-CM) code 493.XX and 1 asthma medication claim in each of the two years of observation. Patients with COPD and diseases associated with chronic oral steroid use were excluded. SABA utilization was converted to canister-count in their fi rst observed quarter and categorized into 0, ½-1, 1½-2, 2. Risk of an asthma exacerbation in the subsequent quarter, defi ned as an oral steroid claim, hospitalization, or ED visit, was assessed using logistic regression, controlling for age, sex, region, and several fi rst-quarter severity measures/ comorbidities. RESULTS: The cohort included 33,951 patients aged 6-17 (36%) and 59653 aged 18-56 (64%) of which 64% had 0 SABA canisters, 18% had ½-1, 9% had 1½-2, and 9% had 2. Compared to 0 canisters, higher SABA utilization was associated with higher exacerbation risk [½-1 (OR:1.01; CI:0.92-1.12), 1½-2 (OR:1.16; CI:1.03-1.31), and 2 (OR:1.47; CI:1.30-1.65)]. Findings were similar when stratifying the sample by age group. CONCLUSIONS: Findings suggest that a quarterly assessment of SABA utilization can be used to identify patients at risk for asthma-related exacerbations. The incidence of an asthma exacerbation was associated with greater SABA use in the previous quarter.
RR2 HEALTH CARE UTILIZATION AND COST OF COPD IN A MEDICAID POPULATION: THE ROLE OF CO-MORBID CONDITIONS
Lin PJ J, Shaya FT University of Maryland, Baltimore, MD, USA OBJECTIVES: Comorbidities in patients with chronic obstructive pulmonary disease (COPD) are associated with higher mortality, hospitalization, and poor quality of life. The objectives of this study were to characterize a comprehensive comorbidity profi le among COPD patients, and to explore the impact of comorbidities on medical utilization and cost in a low-income Medicaid population. METHODS: This retrospective cohort study analyzed medical claims from the Maryland Medicaid database. We employed a 1:2 case-control design to select 1388 COPD patients aged 40 to 64 years with at least 24 months of continuous enrollment and 2776 demographically-matched controls without COPD. Logistic regressions were performed to calculate odds ratios that compared differences in the prevalence of comorbidities, including 17 conditions defi ned by the Charlson Comorbidity Index (CCI) and 6 additional conditions known to coexist with COPD. Generalized linear models were performed to estimate the average medical utilization and cost by specifi c comorbidity. RESULTS: Medicaid COPD patients had more comorbidities compared with non-COPD controls (CCI score 1.56 vs. 1.37, p 0.004), and were more likely to have myocardial infarction, congestive heart failure, cerebrovascular disease, peptic ulcer, mild liver disease, hypertension, sleep apnea, tobacco use, and edema. COPD patients on average had 16 more medical claims (81.4 vs. 65.4, p 0.001) and incurred $1871 higher medical cost per year than non-COPD controls ($7603 vs. $5732, p 0.001). Ten out of the 17 conditions defi ned by the CCI as well as hypertension, tobacco use, and edema were associated with the excess medical utilization and cost in COPD patients. Depression was associated with excess medical utilization but not cost. CONCLUSIONS: Medicaid COPD patients have a substantial burden of comorbidities, which translate into higher medical utilization and cost. Effective disease management and treatment protocols are needed to reduce co-morbidity burden. [ED] visits or hospitalizations for COPD; d2 events occurring within 15 days counted as 1 exacerbation), and use of short-acting inhaled ]2-agonists (SABAs) and ipratropium in the year before therapy began. The number of exacerbations, ED visits, and hospitalizations for COPD; claims for OCS prescriptions; and the average weekly doses (dose 2 inhalations) of SABAs and ipratropium were compared for BUD/FM DPI versus tiotropium DPI users for a 1-year post-therapy period. Poisson and linear regression models were used to produce adjusted rate ratios (RR) and mean differences (MD). RESULTS: Of 981 BUD/FM DPI and 981 tiotropium DPI users in the cohort, 78% were aged "d 65 years and 53% were men. No signifi cant differences were seen for COPD exacerbations (RR 0.94; 95% CI, 0.77-1.15), ED visits for COPD (RR 0.80; 95% CI, 0.54-1.20), and claims for OCS prescriptions (RR 0.93; 95% CI, 0.72-1.21) between BUD/FM DPI and tiotropium DPI users in the year after the start of therapy. However, BUD/FM DPI users had signifi cantly fewer hospitalizations for COPD (RR 0.65; 95% CI, 0.44-0.97), used less SABAs (MD 0.48; 95% CI, 0.67 to 0.28), and used more ipratropium (MD 0.35; 95% CI, 0.21-0.50). CONCLUSIONS: These fi ndings showed that patients using BUD/FM DPI were signifi cantly less likely to have COPD exacerbations leading to a hospitalization, but as likely as tiotropium DPI users to require emergency care or OCS therapy in the year after initiation of therapy.
RR3
USE OF HEALTH CARE SERVICES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATED WITH BUDESONIDE/FORMOTEROL VIA DRY POWDER INHALER (BUD/FM DPI) VERSUS TIOTROPIUM DPI
RR4 OUTCOMES ASSOCIATED WITH TIOTROPIUM USE IN COPD PATIENTS
Lee TA 1 , Wilke CT 2 , Joo M 3 , Stroupe KT 4 , Krishnan JA 5 , Schumock GT 2 , Pickard AS 2 1 Hines VA Hospital and Northwestern University, Chicago, IL, USA, 2 College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 3 Hines VA Hospital and University of Illinois at Chicago, Chicago, IL, USA, 4 Midwest Center for Health Services & Policy Research, Hines, IL, USA, 5 University of Chicago, Chicago, IL, USA OBJECTIVES: To date, there is mixed evidence on the safety and effectiveness of tiotropium. Our objective was to evaluate the comparative effectiveness of regimens containing tiotropium versus other medication regimens for chronic obstructive pul-monary disease (COPD) in real-world clinical settings. METHODS: We conducted a cohort study on two separate cohorts with a diagnosis of COPD in the VA health care system. Patients with a COPD diagnosis prescribed tiotropium and patients in a historic cohort prior to the introduction of tiotropium were selected for comparison using propensity scores, with the base case including scores from 0.1 to 0.4. Outcomes identifi ed during follow-up were all-cause mortality, COPD exacerbations, and COPD hospitalizations. Exposure to COPD medication regimens was defi ned in a time-varying manner and Cox proportional hazards regression were employed to evaluate outcomes. RESULTS: For 42,090 patients in the base case, the regimen of tiotropium plus inhaled corticosteroids plus long-acting beta-agonists was associated with 40% reduced risk of death (HR 0.60 [95% CI 0.45, 0.79]) compared to inhaled corticosteroids plus long-acting beta-agonists. This combination was also associated with reduced rates of COPD exacerbations (HR 0.84 [0.73, 0.97] ) and COPD hospitalizations (HR 0.78 [0.62, 0.98]) . Tiotropium in combination with other medication regimens was associated with increased risk of events compared to inhaled corticosteroids plus long-acting beta-agonists. CONCLUSIONS: When used with inhaled corticosteroids and long-acting beta-agonists, tiotropium use was associated with a decreased risk of mortality compared to treatment with inhaled corticosteroids and long-acting beta-agonists. However, this result was not consistent in other medication regimens that included tiotropium.
POSTER SESSION I CONCEPTUAL PAPERS & RESEARCH ON METHODS -Clinical Outcomes Methods
PMC1 CLASSIFYING PATIENTS WITH METABOLIC SYNDROME USING THE LATENT CLASS ANALYSIS (LCA)
Liu G 1 , Luo N 2 , McCollam PL 3 1 Peking University, Beijing, China, 2 National University of Singapore, Singapore, Singapore, 3 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: To identify subgroups of metabolic syndrome patients who would be more homogeneous in terms of metabolic risk factors. METHODS: The electronic medical record database from GE Healthcare was used for this study. The database comprises de-identifi ed longitudinal medical records of nationally representative patients attending general practitioners. All adult patients were assessed for the presence of metabolic syndrome using the guidelines proposed by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). A latent class analysis was conducted based on the abnormality of patients' metabolic risk factors including triglycerides (TG; 150 mg/dL), high-density lipoprotein cholesterol (HDL-C; men: 40 mg/dL; women: 50 mg/dL), blood pressure (BP; systolic 130 mmHg, diastolic 85 mmHg, or drug treatment for hypertension), fasting plasma glucose ( 100 mg/dL or drug treatment for diabetes mellitus), and waist circumference (WC; men: 102 cm; women: 88 cm). The fi nal model was selected based on model fi t indices including Akaike's information criterion, Bayesian information criterion (BIC), and sample-size adjusted BIC. RESULTS: Metabolic syndrome was present in 19,251 individuals. The prevalence of high blood pressure was 96.4%. All the fi t indices in the LCA modeling pointed to a 5-class solution. In addition to high blood pressure, members of Class 1 (6.5%) had abnormal TG and HDL-C; members of Class 2 (4.6%) had abnormal HDL-C and WC; members of Class 3 (19.7%) had abnormal TG and WC and the majority also had abnormal HDL-C (probability: 68.7%); members of Class 4 (8.2%) had abnormal plasma glucose and WC; and members of Class 5 (61.1%) had high probability of abnormality in all metabolic risk factors (range: 79.9-100%). CONCLUSIONS: LCA represents a new method for casemix study of patients with metabolic syndrome. The subgroups of metabolic syndrome identifi ed in this study need to be further studied for its usefulness in clinical and health services research.
PMC2 LONGITUDINAL DATA EXPLORATION WITH STACKED CUMULATIVE PERCENT PLOTS FOR CATEGORICAL DATA
Gilligan TM g , Hill CD RTI Health Solutions, Research Triangle Park, NC, USA Longitudinal clinical trial data present analysts with the unique challenge of summarizing large trends over time without losing the detail of changes from one timepoint to the next. Analysts must fi nd a balance between the preservation of details at each timepoint and parsimonious output that can be easily summarized and interpreted. For instruments that measure outcomes using nominal or ordinal response categories, analysts may want to preserve categorical information by reporting response category frequencies over time. In this case, the frequency of change across the course of treatment or disease progression is more informative, and perhaps more appropriate, than mean or median change. Collapsing responses into mean or medians draws attention to overall trends, while losing the ability to detect movement from one category response to another. A novel data visualization solution, stacked cumulative percent plots, allows analysts to retain individual categorical responses and track the movement of categorical responses over time. Comparisons of stacked cumulative percent plots with mean plots illustrate the additional information that can be learned from retaining categorical information. Further, a variation of the proposed plot allows analysts to visualize the frequency of response category changes
